dasatinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 785 302962-49-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasatinib
  • sprycel
  • spyrcel
  • BMS-354825
  • dasatinib hydrate
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
  • Molecular weight: 488.01
  • Formula: C22H26ClN7O2S
  • CLOGP: 2.38
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 106.51
  • ALOGS: -4.58
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.85 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 28, 2006 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 1868.83 33.38 461 4112 11207 2342305
Nausea 594.87 33.38 367 4206 111822 2241690
Diarrhoea 515.48 33.38 302 4271 83262 2270250
Fatigue 482.17 33.38 291 4282 84582 2268930
Prescribed underdose 453.21 33.38 106 4467 1956 2351556
Rash 452.03 33.38 247 4326 59311 2294201
Headache 444.91 33.38 271 4302 79908 2273604
Malignant neoplasm progression 403.85 33.38 143 4430 11985 2341527
Dyspnoea 370.47 33.38 240 4333 78493 2275019
Adverse event 355.74 33.38 116 4457 7543 2345969
Pulmonary oedema 299.76 33.38 101 4472 7262 2346250
Death 257.53 33.38 195 4378 81273 2272239
Anaemia 242.59 33.38 137 4436 34655 2318857
Fluid retention 241.43 33.38 85 4488 6961 2346551
Alopecia 240.09 33.38 117 4456 21884 2331628
Vomiting 238.57 33.38 177 4396 71425 2282087
Hospitalisation 227.59 33.38 100 4473 14753 2338759
Pericardial effusion 215.77 33.38 68 4505 3941 2349571
Thrombocytopenia 200.41 33.38 99 4474 19032 2334480
Product dose omission 189.52 33.38 121 4452 38136 2315376
Pneumonia 186.87 33.38 132 4441 49164 2304348
Exposure via body fluid 174.47 33.38 34 4539 244 2353268
Cytogenetic analysis abnormal 171.57 33.38 29 4544 79 2353433
Platelet count decreased 151.27 33.38 77 4496 15736 2337776
Pyrexia 148.21 33.38 119 4454 53589 2299923
Pancytopenia 146.35 33.38 68 4505 11384 2342128
Bone pain 145.53 33.38 63 4510 8933 2344579
Drug resistance 143.16 33.38 45 4528 2579 2350933
Neutropenia 142.15 33.38 82 4491 21466 2332046
Decreased appetite 124.82 33.38 84 4489 28807 2324705
Cough 123.62 33.38 88 4485 33029 2320483
Off label use 119.58 33.38 121 4452 73477 2280035
Myalgia 115.76 33.38 74 4499 23259 2330253
White blood cell count decreased 111.33 33.38 66 4507 18142 2335370
Philadelphia chromosome positive 106.73 33.38 17 4556 27 2353485
Constipation 105.80 33.38 68 4505 21561 2331951
Febrile neutropenia 104.00 33.38 53 4520 10829 2342683
Dehydration 101.47 33.38 67 4506 22228 2331284
Arthralgia 98.70 33.38 95 4478 54190 2299322
Acute lymphocytic leukaemia recurrent 96.06 33.38 20 4553 207 2353305
Pulmonary hypertension 89.82 33.38 38 4535 5080 2348432
Weight decreased 86.93 33.38 67 4506 28304 2325208
Abdominal pain 85.83 33.38 72 4501 34302 2319210
Blast crisis in myelogenous leukaemia 79.57 33.38 16 4557 137 2353375
Pain 77.89 33.38 89 4484 61768 2291744
Colitis 76.03 33.38 34 4539 5192 2348320
Weight increased 75.58 33.38 56 4517 22281 2331231
Pruritus 75.22 33.38 74 4499 43266 2310246
Cardiac failure congestive 74.69 33.38 49 4524 16052 2337460
Drug intolerance 74.20 33.38 46 4527 13671 2339841
Maternal exposure during pregnancy 73.28 33.38 47 4526 14816 2338696
Peripheral swelling 73.10 33.38 50 4523 17547 2335965
Enterocolitis haemorrhagic 70.53 33.38 17 4556 355 2353157
Dizziness 68.13 33.38 81 4492 58584 2294928
Enterococcal bacteraemia 67.67 33.38 14 4559 140 2353372
Chronic myeloid leukaemia 67.58 33.38 18 4555 568 2352944
Pulmonary arterial hypertension 67.10 33.38 29 4544 4081 2349431
Aspiration pleural cavity 66.87 33.38 14 4559 149 2353363
Gastrointestinal haemorrhage 62.97 33.38 40 4533 12395 2341117
Full blood count decreased 60.78 33.38 26 4547 3567 2349945
Bone marrow transplant 59.08 33.38 13 4560 178 2353334
Pleurisy 57.71 33.38 19 4554 1260 2352252
Renal failure 57.55 33.38 43 4530 17306 2336206
Acne 57.10 33.38 24 4549 3152 2350360
Neoplasm malignant 55.08 33.38 27 4546 5066 2348446
Oedema 54.61 33.38 34 4539 10169 2343343
Hypoaesthesia 53.83 33.38 44 4529 20171 2333341
Haemoglobin decreased 53.64 33.38 42 4531 18109 2335403
Stomatitis 53.60 33.38 33 4540 9677 2343835
Chest pain 52.42 33.38 50 4523 28087 2325425
Systemic candida 51.82 33.38 13 4560 322 2353190
Therapeutic response decreased 51.68 33.38 29 4544 7166 2346346
Therapy cessation 51.63 33.38 26 4547 5167 2348345
Neutrophil count decreased 51.37 33.38 28 4545 6539 2346973
Cardiac failure 49.33 33.38 34 4539 12060 2341452
Sepsis 48.71 33.38 40 4533 18448 2335064
Neuropathy peripheral 48.67 33.38 33 4540 11399 2342113
Malaise 47.54 33.38 66 4507 55519 2297993
Muscle spasms 47.31 33.38 42 4531 21524 2331988
Lung infiltration 47.12 33.38 19 4554 2245 2351267
Product use issue 46.80 33.38 33 4540 12136 2341376
Asthenia 46.68 33.38 60 4513 46866 2306646
Dyspnoea exertional 46.44 33.38 25 4548 5695 2347817
Hypertension 46.05 33.38 46 4527 27315 2326197
Migraine 45.94 33.38 31 4542 10622 2342890
Cytopenia 45.57 33.38 15 4558 994 2352518
Bronchitis 45.49 33.38 34 4539 13680 2339832
Lymphoid tissue hyperplasia 44.97 33.38 9 4564 75 2353437
Product use in unapproved indication 44.53 33.38 31 4542 11169 2342343
Subdural haematoma 43.84 33.38 18 4555 2228 2351284
Chronic myeloid leukaemia transformation 43.67 33.38 8 4565 39 2353473
Atrial fibrillation 43.15 33.38 33 4540 13735 2339777
Splenomegaly 42.89 33.38 16 4557 1535 2351977
Normal newborn 41.84 33.38 15 4558 1285 2352227
Large granular lymphocytosis 41.72 33.38 8 4565 52 2353460
Cardiac disorder 41.65 33.38 26 4547 7807 2345705
Skin disorder 41.52 33.38 20 4553 3611 2349901
Dry skin 40.29 33.38 24 4549 6628 2346884
Pain in extremity 40.13 33.38 53 4520 42487 2311025
Generalised oedema 39.36 33.38 17 4556 2386 2351126
Lymphocytosis 39.32 33.38 11 4562 418 2353094
Infection 39.31 33.38 35 4538 17994 2335518
Bone marrow failure 38.35 33.38 22 4551 5664 2347848
Swelling 38.17 33.38 33 4540 16317 2337195
Palpitations 37.98 33.38 33 4540 16423 2337089
Mucosal inflammation 37.36 33.38 21 4552 5203 2348309
Therapy change 36.88 33.38 13 4560 1060 2352452
Skin toxicity 36.70 33.38 12 4561 778 2352734
Hypoxia 36.50 33.38 22 4551 6205 2347307
Abdominal discomfort 36.30 33.38 33 4540 17423 2336089
Nephrotic syndrome 36.29 33.38 13 4560 1111 2352401
Gastrointestinal disorder 36.19 33.38 25 4548 8892 2344620
Stem cell transplant 35.95 33.38 10 4563 372 2353140
Paraesthesia 35.08 33.38 36 4537 22052 2331460
Respiratory failure 35.05 33.38 29 4544 13499 2340013
Dysgeusia 35.00 33.38 24 4549 8435 2345077
Polymerase chain reaction positive 34.13 33.38 6 4567 22 2353490
Musculoskeletal pain 34.02 33.38 26 4547 10804 2342708
Chylothorax 34.01 33.38 7 4566 68 2353444
Influenza 34.00 33.38 28 4545 12950 2340562
Haemorrhage 33.58 33.38 26 4547 11013 2342499

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 2329.06 32.95 600 3970 10510 1731701
Fatigue 511.68 32.95 301 4269 50480 1691731
Malignant neoplasm progression 475.51 32.95 192 4378 13966 1728245
Headache 423.70 32.95 233 4337 34143 1708068
Diarrhoea 396.67 32.95 262 4308 53590 1688621
Prescribed underdose 372.87 32.95 94 4476 1414 1740797
Adverse event 275.72 32.95 96 4474 4572 1737639
Death 270.10 32.95 255 4315 87188 1655023
Rash 268.58 32.95 182 4388 38511 1703700
Pulmonary oedema 257.66 32.95 100 4470 6486 1735725
Nausea 257.60 32.95 198 4372 50998 1691213
Dyspnoea 256.85 32.95 199 4371 51860 1690351
Fluid retention 254.78 32.95 86 4484 3723 1738488
Drug resistance 252.33 32.95 82 4488 3148 1739063
Hospitalisation 227.15 32.95 111 4459 12589 1729622
Pyrexia 214.75 32.95 171 4399 46229 1695982
Pericardial effusion 212.77 32.95 73 4497 3317 1738894
Pneumonia 206.87 32.95 167 4403 46015 1696196
Blast crisis in myelogenous leukaemia 176.19 32.95 36 4534 190 1742021
Thrombocytopenia 154.07 32.95 103 4467 21146 1721065
Febrile neutropenia 151.69 32.95 81 4489 11019 1731192
Anaemia 149.73 32.95 115 4455 29342 1712869
Platelet count decreased 144.13 32.95 90 4480 16433 1725778
Decreased appetite 143.22 32.95 103 4467 23768 1718443
Drug intolerance 142.21 32.95 64 4506 5998 1736213
Chronic myeloid leukaemia 135.80 32.95 36 4534 662 1741549
Product dose omission 130.40 32.95 95 4475 22345 1719866
Pulmonary hypertension 115.48 32.95 44 4526 2698 1739513
Large granular lymphocytosis 114.69 32.95 20 4550 34 1742177
Pancytopenia 109.49 32.95 66 4504 11291 1730920
Off label use 103.82 32.95 105 4465 38466 1703745
Cytogenetic analysis abnormal 100.77 32.95 19 4551 60 1742151
Chylothorax 97.31 32.95 20 4550 109 1742102
Acne 94.45 32.95 34 4536 1774 1740437
Vomiting 93.52 32.95 99 4471 38216 1703995
Oedema 90.04 32.95 49 4521 6899 1735312
Myalgia 87.91 32.95 65 4505 15593 1726618
Philadelphia chromosome positive 86.58 32.95 15 4555 24 1742187
Acquired gene mutation 83.65 32.95 19 4551 176 1742035
Cough 80.33 32.95 67 4503 19130 1723081
Weight decreased 80.23 32.95 72 4498 22681 1719530
Arthralgia 78.38 32.95 72 4498 23372 1718839
Neutropenia 72.82 32.95 62 4508 18198 1724013
Bone pain 70.92 32.95 33 4537 3329 1738882
Pain 70.53 32.95 72 4498 26585 1715626
Aspiration pleural cavity 67.67 32.95 15 4555 123 1742088
Cardiac failure 65.54 32.95 50 4520 12552 1729659
Chest pain 64.27 32.95 60 4510 19854 1722357
Haemoglobin decreased 63.95 32.95 56 4514 17058 1725153
Therapy cessation 63.70 32.95 30 4540 3109 1739102
Oedema peripheral 62.39 32.95 53 4517 15497 1726714
Respiratory failure 59.34 32.95 50 4520 14455 1727756
Dehydration 58.51 32.95 54 4516 17604 1724607
Pulmonary arterial hypertension 58.28 32.95 23 4547 1547 1740664
Infection 57.67 32.95 46 4524 12314 1729897
Atrial fibrillation 57.56 32.95 50 4520 15061 1727150
White blood cell count decreased 57.26 32.95 47 4523 13102 1729109
Pleurisy 54.96 32.95 19 4551 878 1741333
Abdominal pain 54.91 32.95 57 4513 21433 1720778
Gene mutation 54.64 32.95 13 4557 150 1742061
Colitis 52.79 32.95 29 4541 4151 1738060
Sepsis 52.26 32.95 53 4517 19385 1722826
Abdominal discomfort 51.57 32.95 38 4532 9043 1733168
Abdominal pain upper 51.43 32.95 41 4529 10960 1731251
Acute lymphocytic leukaemia recurrent 51.30 32.95 14 4556 288 1741923
Malaise 51.05 32.95 64 4506 29501 1712710
Bone marrow transplant 50.30 32.95 13 4557 215 1741996
Musculoskeletal pain 50.14 32.95 30 4540 5044 1737167
Cardiac failure congestive 49.22 32.95 46 4524 15224 1726987
Lymphoid tissue hyperplasia 49.20 32.95 10 4560 51 1742160
Graft versus host disease 48.17 32.95 20 4550 1533 1740678
Constipation 47.99 32.95 45 4525 14955 1727256
Peripheral swelling 46.72 32.95 34 4536 7937 1734274
Blast cell proliferation 46.48 32.95 8 4562 12 1742199
Multiple-drug resistance 46.34 32.95 13 4557 297 1741914
Therapy change 46.23 32.95 16 4554 742 1741469
Asthenia 46.00 32.95 66 4504 34604 1707607
Pain in extremity 45.38 32.95 48 4522 18424 1723787
Swelling 43.65 32.95 31 4539 6965 1735246
Neoplasm recurrence 42.54 32.95 13 4557 404 1741807
Back pain 42.29 32.95 44 4526 16569 1725642
Drug ineffective 41.92 32.95 89 4481 63712 1678499
Pericarditis 41.69 32.95 18 4552 1520 1740691
Treatment failure 40.85 32.95 25 4545 4376 1737835
Gastrointestinal haemorrhage 40.34 32.95 40 4530 14227 1727984
Haemothorax 39.78 32.95 14 4556 682 1741529
Muscle spasms 39.35 32.95 36 4534 11585 1730626
Hyphaema 38.90 32.95 9 4561 91 1742120
Electrocardiogram QT prolonged 37.92 32.95 26 4544 5519 1736692
Peripheral arterial occlusive disease 37.74 32.95 14 4556 794 1741417
Product use in unapproved indication 37.51 32.95 32 4538 9390 1732821
Transfusion 36.70 32.95 15 4555 1104 1741107
Neoplasm malignant 36.11 32.95 23 4547 4316 1737895
Full blood count decreased 35.55 32.95 19 4551 2573 1739638
Gene mutation identification test positive 35.13 32.95 8 4562 75 1742136
Dyspnoea exertional 34.49 32.95 22 4548 4139 1738072
Mucosal inflammation 34.45 32.95 22 4548 4147 1738064
Acute kidney injury 34.40 32.95 58 4512 34886 1707325
Memory impairment 33.64 32.95 26 4544 6637 1735574
Anterior interosseous syndrome 33.63 32.95 5 4565 0 1742211
Pruritus 33.42 32.95 46 4524 23176 1719035

Pharmacologic Action:

SourceCodeDescription
ATC L01XE06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Blastic phase chronic myeloid leukemia indication 413656006
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Torsades de pointes contraindication 31722008
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Pleural Effusions contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.56 acidic
pKa2 7.72 Basic
pKa3 4.89 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR THE TREATMENT OF CANCER
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR THE TREATMENT OF CANCER
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR THE TREATMENT OF CANCER
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR THE TREATMENT OF CANCER
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR THE TREATMENT OF CANCER
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR THE TREATMENT OF CANCER
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 7125875 April 13, 2020 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL 7153856 April 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 7153856 April 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7153856 April 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7153856 April 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 7153856 April 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 7153856 April 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF CANCER
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL 6596746 June 28, 2020 A METHOD FOR THE TREATMENT OF CANCER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Nov. 9, 2020 NEW PATIENT POPULATION
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2020 NEW PATIENT POPULATION
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2020 NEW PATIENT POPULATION
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2020 NEW PATIENT POPULATION
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2020 NEW PATIENT POPULATION
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2020 NEW PATIENT POPULATION
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL May 9, 2021 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2021 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2021 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2021 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2021 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2021 PEDIATRIC EXCLUSIVITY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Dec. 21, 2021 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2021 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2021 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2021 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2021 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2021 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.24 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Tyrosine-protein kinase Fyn Kinase INHIBITOR Kd 9.10 CHEMBL CHEMBL
Tyrosine-protein kinase Yes Kinase INHIBITOR Kd 9.52 CHEMBL CHEMBL
Ephrin type-A receptor 2 Kinase INHIBITOR Kd 9.07 CHEMBL CHEMBL
Tyrosine-protein kinase Lck Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 9.20 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR IC50 9.60 IUPHAR CHEMBL
Serine/threonine-protein kinase mTOR Kinase IC50 4.46 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase Kd 5.54 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.11 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 9.33 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 5.82 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.51 CHEMBL
Myelin transcription factor 1 Unclassified IC50 7.20 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 9.47 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.92 CHEMBL
Aurora kinase A Kinase Kd 5.03 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.48 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.35 CHEMBL
MAP kinase p38 Kinase IC50 7 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.54 CHEMBL
Wee1-like protein kinase Kinase Kd 5.15 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 8.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 5.28 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 8.39 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase Nek11 Kinase Kd 6.33 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.30 CHEMBL
Tyrosine-protein kinase Fgr Kinase INHIBITOR Kd 9.30 CHEMBL
Serine/threonine-protein kinase MRCK alpha Kinase Kd 5.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.43 CHEMBL
Tyrosine-protein kinase FRK Kinase INHIBITOR Kd 9.51 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 9.62 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 10.03 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.19 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 9 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 7.96 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase HCK Kinase INHIBITOR Kd 9.46 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.43 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.85 CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 5.47 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 6.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.35 CHEMBL
Misshapen-like kinase 1 Kinase Kd 6.37 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.68 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.26 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 5.68 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.70 CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Kinase Kd 6.89 CHEMBL
Aurora kinase B Kinase IC50 5.19 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6.14 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 7.28 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 5.42 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 8.11 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.27 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 5.19 CHEMBL
Tyrosine-protein kinase Lyn Kinase INHIBITOR Kd 9.24 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 8.85 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 9.62 CHEMBL
LIM domain kinase 1 Kinase Kd 6.24 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 8.92 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 9.35 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.42 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 8.25 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.19 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 7.48 CHEMBL
Activin receptor type-1 Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase MRCK gamma Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.34 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 9.77 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.72 CHEMBL
Activin receptor type-2B Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase Blk Kinase INHIBITOR Kd 9.68 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 7.74 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 10.41 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.52 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 8.19 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.64 CHEMBL
Tyrosine-protein kinase Srms Kinase INHIBITOR Kd 7.89 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 7.55 CHEMBL
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 Kinase IC50 5.77 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 6.70 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 9.24 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.52 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 6.34 CHEMBL
Activin receptor type-1B Kinase Kd 6.48 CHEMBL
Bone morphogenetic protein receptor type-1A Kinase Kd 5.15 CHEMBL
TGF-beta receptor type-1 Kinase Kd 6.64 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.54 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.80 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.41 CHEMBL
Myotonin-protein kinase Kinase Kd 5.89 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.16 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.51 CHEMBL
Activin receptor type-2A Kinase Kd 6.68 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.46 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.10 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 9.41 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.39 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 8.68 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 5.49 CHEMBL
LIM domain kinase 2 Kinase Kd 7.07 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 8.16 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 7.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.59 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 8.41 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 7.57 CHEMBL
Bcr/Abl fusion protein Kinase IC50 9.10 CHEMBL
Breakpoint cluster region protein Kinase WOMBAT-PK
Cyclin-G-associated kinase Kinase Kd 8.59 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.49 CHEMBL
Epidermal growth factor receptor Kinase Kd 7.10 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.30 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 7.96 CHEMBL
Tyrosine-protein kinase Blk Kinase IC50 8.10 CHEMBL
Proto-oncogene tyrosine-protein kinase LCK Kinase Ki 10.19 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.19 CHEMBL
Tubulin alpha-1A chain Structural Kd 7.26 CHEMBL

External reference:

IDSource
D000069439 MESH_DESCRIPTOR_UI
4025488 VUID
N0000179780 NUI
C1455147 UMLSCUI
D03658 KEGG_DRUG
422756008 SNOMEDCT_US
21648 MMSL
d05831 MMSL
475342 RXNORM
4025488 VANDF
423658008 SNOMEDCT_US
011616 NDDF
CHEMBL1421 ChEMBL_ID
RBZ1571X5H UNII
863127-77-9 SECONDARY_CAS_RN
1N1 PDB_CHEM_ID
DB01254 DRUGBANK_ID
CHEBI:49375 CHEBI
5678 IUPHAR_LIGAND_ID
3062316 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0524 TABLET 70 mg ORAL NDA 19 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0527 TABLET 20 mg ORAL NDA 19 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0528 TABLET 50 mg ORAL NDA 19 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0852 TABLET 100 mg ORAL NDA 19 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0855 TABLET 80 mg ORAL NDA 19 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0857 TABLET 140 mg ORAL NDA 19 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 54868-5759 TABLET 70 mg ORAL NDA 19 sections